Surgery in testis cancer: Laparoscopic and open techniques

Current Opinion in Urology

Volumn 12, Issue 5, 2002, Pages 435-440

  Albers, Peter ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Laparoscopic surgery; Residual tumor resection; Surgery; Testis cancer

Indexed keywords

CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MALE; OPERATION DURATION; PARAAORTIC LYMPH NODE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SEMINOMA; SURGICAL TECHNIQUE; TESTIS CANCER;

GERMINOMA; HUMANS; LAPAROSCOPY; MALE; NEOPLASM STAGING; TESTICULAR NEOPLASMS;

EID: 0036739822     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200209000-00012     Document Type: Review

References (48)

1. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10:1762-1768.
2. Klepp O, Dahl O, Flodgren P, et al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997; 33:1038-1044.
3. Ondrus D, Matoska J, Belan V, et al. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 1998; 33:562-566.
4. Albers P, Siener R, Hartmann M, et al. Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group. Int J Cancer 1999; 83:828-830.
5. Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 1993; 71:326-335.
6. Baniel J, Foster RS, Rowland RG, et al. Complications of primary retroperitoneal lymph node dissection. J Urol 1994; 152(2 Pt 1):424-427.
7. Sharir S, Jewett MA, Sturgeon JF, et al. Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the follow-up protocol J Urol 1999; 161:472-475; discussion 475-476.
8. Heidenreich A, Albers P, Kliesch S, et al. Morbidity of primary nerve-sparing retroperitoneal lymph node dissection in clinical stage I nonseminomatous testis cancer [Abstract]. J Urol 2002; 167:154.
9. Donohue JP, Thornhill JA, Foster RS, et al. Clinical stage B nonseminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 1995; 31A:1599-1604.
10. Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000; 163:1721-1724.
11. Sweeney CJ, Hermans BP, Heilman DK, et al. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J Clin Oncol 2000; 18:358-362.
12. Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997; 8:41-47.
13. Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol 1995; 154:1370-1372.
14. Foster RS, Donohue JP. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol 2000; 163:1788-1792.
15. Nelson JB, Chen RN, Bishoff JT, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999; 54:1064-1067.
16. Rassweiler JJ, Frede T, Lenz E, et al. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000; 37:251-260.
17. Hobisch A, Peschel R, Höltl L, et al. Experience of more than 150 laparoscopic retroperitoneal lymph node dissections of testicular tumors - technique and results [Abstract]. Eur Urol 2002; 1(Suppl 1):94.
18. Janetschek G, Hobisch A, Peschel R, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 2000; 163:1793-1796.
19. Janetschek G, Peschel R, Hobisch A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection. J Endourol 2001; 15:449-453; discussion 453-455.
20. LeBlanc E, Caty A, Dargent D, et al. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results. J Urol 2001; 165:89-92.
21. Janetschek G. Laparoscopic retroperitoneal lymph node dissection. Urol Clin North Am 2001; 28:107-114.
22. Höltl L, Peschel R, Knapp R, et al. Primary lymphatic metastatic spread in testicular cancer occurs ventral to the lumbar vessels. Urology 2002; 59:114-118.
23. Horwich A, Huddart R, Dearnaley D. Markers and management of germ-cell tumours of the testes [Review]. Lancet 1998; 352(9139):1535-1538.
24. Weissbach L, Bussar-Maatz R, Flechtner H, et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000; 37:582-594.
25. Steiner H, Peschel R, Höltl L, et al. Laparoscopic retroperitoneal lymph node dissection is feasible after chemotherapy fro retroperitoneal stage II nonseminomatous germ cell tumors [Abstract]. J Urol 2002; 167:170.
26. Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 1997; 80:653-657.
27. Albers P, Weinknecht S, Krege S, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors - results of a prospective multicenter trial of the GTCSG [Abstract]. J Urol 2002; 167:172.
28. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19:3740-3744.
29. Mosharafa A, Foster RS, Leibovich BC, et al. Is the post chemotherapy resection of seminomatous elements associated with higher acute morbidity [Abstract]? J Urol 2002; 167:172.
30. Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997; 15:1455-1464.
31. Ganjoo KN, Foster RS, Michael H, et al. Germ cell tumor associated primitive neuroectodermal tumors. J Urol 2001; 165:1514-1516.
32. Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998; 83:1409-1419.
33. Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002; 94:1668-1676.
34. Steyerberg EW, Keizer HJ, Habbema JD. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer 1999; 83:856-859.
35. Eastham JA, Wilson TG, Russell C, et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994; 43:74-80.
36. Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000; 164:381-384.
37. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995; 13:1177-1187.
38. Steyerberg EW, Gerl A, Fossa SD, et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 1998; 16:269-274.
39. Vergouwe Y, Steyerberg EW, Foster RS, et al. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J Urol 2001; 165:84-88; discussion 88.
40. Foster RS, Donohue JP. Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? Urol Clin North Am 1998; 25:479-484.
41. Sheinfeld J, Herr HW. Role of surgery in management of germ cell tumor. Semin Oncol 1998; 25:203-209.
42. Coogan CL, Hejase MJ, Wahle GR, et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996; 156:1656-1658.
43. Arai Y, Ishitoya S, Okubo K, et al. Nerve-sparing retroperitoneal lymph node dissection for metastatic testicular cancer. Int J Urol 1997; 4:487-492.
44. Jacobsen KD, Ous S, Waehre H, et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 1999; 80:249-255.
45. Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995; 153(3 Pt 2):976-980.
46. Gels ME, Nijboer AP, Hoekstra HJ, et al. Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. Br J Urol 1997; 79:263-268.
47. Steyerberg EW, Donohue JP, Gerl A, et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol 1997; 158:474-478.
48. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 2001; 19:2647-2657.